Haoyuan pharmaceutical: it plans to purchase 100% equity shares of drug source drugs and suspend trading
Haoyuan pharmaceutical announced that the company plans to acquire 100% equity of drug source drugs held by Wang Yuan, Shanghai Yuanmeng enterprise management consulting partnership (limited partnership), Qidong Yuanli enterprise management consulting partnership (limited partnership) and Ningbo Jiusheng innovative pharmaceutical technology Co., Ltd. by issuing shares and paying cash, At the same time, it is proposed to issue shares to the controlling shareholder of the company, Shanghai Anshu Information Technology Co., Ltd., to raise supporting funds of no more than 50 million yuan. The trading of the company's shares has been suspended since February 21, and the suspension is expected to be no more than 10 trading days.
This text is a result of machine translation.
Related companies：
In-depth
Technology
DeepSeek | China's AI Global Breakthrough and Ecosystem Restructuring
Mar 19, 2025 01:18 PM
Jan 30, 2024 07:59 PM
Dec 11, 2023 08:49 PM
Jan 05, 2023 07:33 PM
Nov 16, 2022 05:19 PM
Technology
SoftBank Group Plans to Raise USD 16.5 Bn for the "Stargate" AI Project
Apr 02, 2025 04:10 PM
Briefing Dec 15, 2021 02:09 PM
· Consumer Discretionary
Huawei announces vehicle traffic command patent
Technology
Intel's New CEO: Spin Off Non-core Businesses and Focus on Chip Manufacturing
Apr 02, 2025 04:05 PM
Briefing Nov 30, 2021 08:39 PM
· Consumer Discretionary
Guanglian Airlines: Lu Yan, the shareholder, plans to reduce his shares by no more than 2.24%
See more
Read next
Insight
In-depth
Insight
In-depth
